BackgroundCheck.run
Search For

Ann H Horan Deceased10 Fairmont Ave, Millstone, NJ 08876

Ann Horan Phones & Addresses

10 Fairmont Ave, Somerville, NJ 08876    908-6850506    908-7229324   

New York, NY   

South Salem, NY   

Duxbury, MA   

22 Gilbert St, South Salem, NY 10590    908-7229324   

Work

Position: Building and Grounds Cleaning and Maintenance Occupations

Education

Degree: Bachelor's degree or higher

Mentions for Ann H Horan

Career records & work history

License Records

Ann Horan

Licenses:
License #: 79701 - Expired
Category: Nursing Support
Issued Date: Jun 14, 2007
Effective Date: Jun 16, 2009
Type: Nurse Aide

Ann Horan resumes & CV records

Resumes

Ann Horan Photo 46

Consultant

Location:
Ocean Grove, NJ
Industry:
Pharmaceuticals
Work:
Society For Industrial Microbiology and Biotechnology 1994 - 2004
Member of Board
Microbiology Advisors 1994 - 2004
Consultant
Education:
Waksman Institute of Microbiology 1966 - 1971
Ann Horan Photo 47

Ann Horan

Ann Horan Photo 48

Vice President At Bank Of New York Mellon

Location:
United States
Industry:
Financial Services
Ann Horan Photo 49

Vp At Jpmc

Location:
Greater New York City Area
Industry:
Financial Services
Ann Horan Photo 50

Assistant Designer At Sign-A-Rama

Location:
Greater New York City Area
Industry:
Retail
Ann Horan Photo 51

Vp At Jpmc

Location:
Greater New York City Area
Industry:
Financial Services

Publications & IP owners

Us Patents

Isolated Nucleic Acids From Micromonospora Rosaria Plasmid Pmr2 And Vectors Made Therefrom

US Patent:
6569668, May 27, 2003
Filed:
Mar 29, 2001
Appl. No.:
09/821167
Inventors:
Ann C. Horan - Summit NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 120
US Classification:
4352523, 4353201, 536 231, 536 237
Abstract:
Plasmid genes from pMR2 have been isolated, cloned, sequenced and functionally identified. These genes have been used to create vectors which can be used to express actinomycete genes, manipulate metabolic pathways and produce useful gene products such as hybrid antibiotics.

Everninomicin Biosynthetic Genes

US Patent:
6861513, Mar 1, 2005
Filed:
Jan 11, 2001
Appl. No.:
09/758759
Inventors:
Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07H021/04
US Classification:
536 231, 4353201, 4352523, 435471
Abstract:
This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A. site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

Isolation Of Var Africana Pmlp1 Integrase And Use Of Integrating Function For Site-Specific Integration Into And Chromosome

US Patent:
7220567, May 22, 2007
Filed:
May 15, 2001
Appl. No.:
09/855340
Inventors:
Ann C. Horan - Summit NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 1/21
C12N 15/00
C12N 15/74
C07H 21/04
US Classification:
4352523, 4353201, 435471, 536 231, 536 237
Abstract:
Plasmid genes from var. ATCC39149 pMLP1 have been isolated cloned, sequenced and functionally identified. These genes have been used to create vectors which integrate in a site-specific manner into the host chromosome of actinomycete species.

Everninomicin Biosynthetic Proteins

US Patent:
7229813, Jun 12, 2007
Filed:
Dec 23, 2004
Appl. No.:
11/021825
Inventors:
Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 9/10
C12N 15/74
C12N 15/64
C12N 1/20
C12N 1/00
C12P 21/06
C07H 21/04
US Classification:
435193, 435 691, 435 914, 4352523, 43525411, 435471, 536 231, 536 232
Abstract:
This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

Everninomicin Biosynthetic Genes

US Patent:
7790411, Sep 7, 2010
Filed:
Apr 25, 2007
Appl. No.:
11/739945
Inventors:
Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12P 21/06
C12P 19/34
C12N 15/00
C12N 1/20
C12N 15/07
C07H 21/02
C07H 21/04
US Classification:
435 691, 435 911, 435183, 4352521, 4353201, 435471, 536 231, 536 232, 536 237
Abstract:
This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

Everninomicin Biosynthetic Genes

US Patent:
7947480, May 24, 2011
Filed:
Sep 3, 2010
Appl. No.:
12/875342
Inventors:
Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 9/02
C12N 9/00
C12N 15/00
C12N 1/20
C12P 21/06
C12P 19/34
A61K 39/395
C07H 21/02
C07H 21/04
US Classification:
435189, 435183, 435 691, 435 911, 4353201, 4352523, 4241301, 4241461, 536 231, 536 232
Abstract:
This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

Everninomicin Biosynthetic Genes

US Patent:
2011026, Nov 3, 2011
Filed:
May 2, 2011
Appl. No.:
13/098645
Inventors:
Thomas J. Hosted - Summit NJ, US
Tim X. Wang - Roselle Park NJ, US
Ann C. Horan - Summit NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 15/63
C07H 21/04
C12N 1/21
US Classification:
43525233, 4353201, 4352523, 536 231, 536 234, 536 232
Abstract:
This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

Actinomadura Vulgaris Subsp Vulgaris And Antimicrobial Complex And Antimicrobial

US Patent:
5837691, Nov 17, 1998
Filed:
Aug 12, 1991
Appl. No.:
7/747456
Inventors:
Vinod R. Hegde - Parsippany NJ
Ann C. Horan - Summit NJ
Mahesh G. Patel - Verona NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 3171
C07H 1708
US Classification:
514 29
Abstract:
A novel macrolactam monosaccharide isolated from an antimicrobial complex 517 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism Actinomadura vulgaris subsp. vulgaris ATCC 53748.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.